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Abstract
The knowledge of genomic DNA variations in patient samples has a high and increasing
value for human diagnostics in its broadest sense. Although many methods and sensors to
detect or quantify these variations are available or under development, the number of under-
lying physico-chemical detection principles is limited. One of these principles is the hybrid-
ization of sample target DNA versus nucleic acid probes. We introduce a novel
thermodynamics approach and develop a framework to exploit the specific detection capa-
bilities of nucleic acid hybridization, using generic principles applicable to any platform. As a
case study, we detect point mutations in the KRAS oncogene on a microarray platform. For
the given platform and hybridization conditions, we demonstrate the multiplex detection
capability of hybridization and assess the detection limit using thermodynamic consider-
ations; DNA containing point mutations in a background of wild type sequences can be iden-
tified down to at least 1% relative concentration. In order to show the clinical relevance, the
detection capabilities are confirmed on challenging formalin-fixed paraffin-embedded clini-
cal tumor samples. This enzyme-free detection framework contains the accuracy and effi-
ciency to screen for hundreds of mutations in a single run with many potential applications in
molecular diagnostics and the field of personalised medicine.
Introduction
The advent of whole-genome-sequencing has led to a tremendous increase in genetic loci that
can be employed for molecular diagnostic tests. In particular, the detection of high-resolution
genomic alterations, such as single-nucleotide variants (SNVs), are becoming progressively
important in human diagnostics. For example, several known DNA mutations have been asso-
ciated with clinical syndromes, disease prognosis or can be utilized to predict the response to
therapy. Especially modern cancer therapies have a varying efficacy across a patient
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population, which in turn can be associated to the genomic variation. A case in point are muta-
tions in the RAS oncogene family that predict patient response to EGFR-inhibiting drugs such
as panitumumab (Vectibix) and cetuximab (Erbitux) [1]. Confident and swift detection of
these single nucleotide substitutions are performed by different techniques [2–4], often non-
sequencing molecular technologies as they can be miniaturized and easily adjusted for clinical
practice. For this purpose, qPCR seems the most widely used technology in clinical laborato-
ries (see also www.fda.gov/companiondiagnostics). The idea to use hybridization based tech-
nologies, e.g. microarrays, for mutation detection is not new [5], but it is rather uncommon.
This observation seems somewhat surprising given the fact that hybridization technology is
nowadays mature, affordable, widely used and versatile towards type and number of nucleic
acid sequences to target for diagnostic tests. Moreover, hybridization as a system for SNV
detection can be seen as a simple reversible and enzyme-free process. However, for a clear
quantitative interpretation of microarray data, insight and use of the physico-chemical founda-
tions of the hybridization process turn out to be crucial, especially because diagnostic applica-
tions impose specific constraints.
Competitive hybridization of different target sequences with the probe is the culprit that
complicates the quantitative analysis. As proposed in previous work [6–8], hybridization of
nucleic acid strands is a process that can be quantitatively modelled by the theory of thermody-
namics. Physico-chemical modeling of nucleic acid hybridization enables the computation of
free energies in pairs of single stranded target DNA and probe DNA after thermodynamic
equilibrium has been reached. These free energies can in turn be used to differentiate between
standard and non-standard Watson-Crick pairings for a particular probe-target interaction.
This latter finding is especially powerful in human diagnostics where target DNA sequences
will compete for hybridization at the set of probes.
In this work, we apply the theoretical concepts of DNA thermodynamics to present a quan-
titative hybridization-based technology to account for competitive hybridization, enabling a
direct identification of SNV, and a framework to determine the detection limit. The data of
this manuscript is produced on a microarray platform but the principles are platform-free and
apply to any hybridization based sensor. To proof the concept of this new diagnostic tool, we
apply our model to the measurement of point mutations in the KRAS oncogene, an important
genetic marker for colorectal and lung cancer diagnostics and treatment stratification [9–11].
The technical challenges associated with this measurement are complicated because the set of
relevant and approved biomarkers is changing over time and comprises a panel of markers
instead of one specific mutation. Furthermore, the heterogeneity of the tissue material in the
tumor is an unknown parameter (the ratio of cancer versus non-cancer cells in a clinical sam-
ple is variable and the DNA mutations can be heterozygous or homozygous origin) and
requires a rigorous assessment of the detection limits. In addition, the tumor DNA is often of
lower quality, since it is derived from formalin-fixed paraffin-embedded (FFPE) tissue. In
order to illustrate that the hybridization-based technology is flexible and robust, and allows
multiplexing of several mutations with a desired detection limit, we have designed three con-
trolled sets of experiments:
Firstly, a typical clinical tumor sample has cancer cells (that contain the DNA mutation)
present in minority. It is usually possible to take samples with more than 10% cancer cells but
the ratio cancer/normal tissue is unknown prior the experimentation. The first aim of our
study is the development of a method based on hybridization thermodynamics to assess the
limit of detection with respect to the relative concentration of mutant DNA. For this purpose
Experiment set 1 described in Materials and Methods is generated.
Secondly, in clinical DNA diagnostics, it is often needed to check for more than one possi-
ble mutation. In our case we focus on the twelve (mutually exclusive) possible point mutations
DNA mutation hybridization framework
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in exon 2 of the KRAS gene and aim to assess each of them a single experiment. Hence we test
the parallelization capability of the method as described in Experiment set 2.
Thirdly, clinical tumor tissue are often conserved as FFPE samples. As a consequence, DNA
extracted from this FFPE material is of low quality due to cross-linking between nucleic acids
and proteins and nucleic acid fragmentation. Therefore the third and obvious goal is to test
real clinical FFPE tumor samples as described in Experiment set 3.
Materials and methods
Experimental setup
In the present study we define three sets of experiments, corresponding to the three goals men-
tioned in the introduction. The first two experimental sets consist of samples in which we use
synthetic DNA (PCR amplified gBlocks, see sample preparation) and control the ratio of
mutant over wild type. The third experimental set consists of DNA extracted from clinical
tumor samples (see sample preparation).
1. Experiment set 1 contains a dilution series of one mutation type, see Table 1, while keeping
a constant total concentration of single stranded (ss) DNA.
2. Experiment set 2 covers the 12 most commonly reported KRAS mutations, see Table 2, each
at a relative mutant concentration of 5%. A wild type sample is used as negative control.
3. Experiment set 3 consists of 7 clinical tumor samples, for which the mutant % is unknown.
FFPE colon carcinoma samples from the Center of Medical Genetics Ghent, were analyzed
in a blinded manner and compared with available sanger sequencing data. As a wild type
reference the genomic DNA of a blood sample of a healthy individual was used.
Probeset design
A microarray contains a number of predefined spots, which are local spaces on the array sur-
face that contain many physically associated ssDNA copies of a given sequence (called probe
sequence). An experiment begins with the hybridization of all the independent spots with a
provided sample, i.e. an amount of the fluorescently labeled target ssDNA in solution. After
hybridization and washing, the measurement consists of a determination of the fluorescent
intensity I of each spot, which is proportional to the amount of target that hybridized to the
corresponding probes. A probeset is the whole set of different probes which are designed and
immobilized for a particular microarray experiment.
For our microarray experiments, we constructed a custom designed probeset as follows.
Our study focuses on the region around codon 12 and 13 of exon 2 of the KRAS gene. From
this sequence, the optimal probe length is derived: based on previous experimental experience
[6] we estimated that a suited probe-target affinity would be achieved for probes of length 23
nucleotides. This results in the wild type target sequence of interest: 5’-GTTGGAGCTGGTGG
CGTAGGCAA-3’. From this sequence, a probeset was designed (see Table 3). This probeset
Table 1. Dilution series for one mutation type.
relative DNA concentration of mutant 10C!G
cmut/ctotal 0.10% 0.26% 0.64% 1.6% 4.0% 10%
Six synthetic samples in experiment set 1, containing mutation G12A (10C!G) with relative concentration
as listed, dilution factor 2.5, total concentration of 5nM.
https://doi.org/10.1371/journal.pone.0177384.t001
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Table 2. Wild type and mutants sequences.
Wild type sequence
wild type 50   . . .CCTACGCC|ﬄ{zﬄ}
13
ACC|ﬄ{zﬄ}
12
AGCTCC. . .   30
Mutant sequences
Nucleotide notation Amino acid notation
9C!A G12C . . .GCCACA. . .
9C!T G12S . . .GCCACT. . .
9C!G G12R . . .GCCACG. . .
10C!T G12D . . .GCCATC. . .
10C!G G12A . . .GCCAGC. . .
10C!A G12V . . .GCCAAC. . .
12C!A G13C . . .GCAACC. . .
12C!T G13S . . .GCTACC. . .
12C!G G13R . . .GCGACC. . .
13C!T G13D . . .GTCACC. . .
13C!G G13A . . .GGCACC. . .
13C!A G13V . . .GACACC. . .
This table shows the 12 most commonly reported mutation types in exon 2 of the KRAS oncogene. All 12 are
enclosed in experiment set 2 as gBlocks samples with a relative mutation amount of 5%. The first column
shows the mutation types in nucleotide notation. The numbers 9 to 13 are merely nucleotide position
counters of the probe region, they were introduced by us and are used in the Results section. The second
column shows the amino acid notation: e.g. G12C is a mutation on codon 12 changing the wild type gly-G
amino acid into cys-C. The third column shows the corresponding nucleotide sequence with the nucleotide
mutation shown in bold.
https://doi.org/10.1371/journal.pone.0177384.t002
Table 3. Wild type and mutants sequences.
target
wild type 5’-TTGCCTACGCCACCAGCTCCAAC-3’
probe
probe 3’-AACGGATGCGGTGGTCGAGGTTG-5’
1 MM 3’-AACGAATGCGGTGGTCGAGGTTG-5’
3’-AACGTATGCGGTGGTCGAGGTTG-5’
3’-AACGCATGCGGTGGTCGAGGTTG-5’
3’-AACGGTTGCGGTGGTCGAGGTTG-5’
3’-AACGGCTGCGGTGGTCGAGGTTG-5’
3’-AACGGGTGCGGTGGTCGAGGTTG-5’
. . .
2 MM 3’-AACGAATGCAGTGGTCGAGGTTG-5’
3’-AACGAATGCTGTGGTCGAGGTTG-5’
3’-AACGAATGCCGTGGTCGAGGTTG-5’
3’-AACGAATGCGATGGTCGAGGTTG-5’
3’-AACGAATGCGTTGGTCGAGGTTG-5’
3’-AACGAATGCGCTGGTCGAGGTTG-5’
. . .
This table sketches the probeset design. Probes contain zero, one or two mismatches against the wild type
target. We did not introduce mismatches that are either too close to each other or near the boundaries to
avoid extra penalty on the free energy (affinity) [7]. PM = perfect match, MM = mismatch
https://doi.org/10.1371/journal.pone.0177384.t003
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contains one perfectly matching (PM) probe against the target wild type. The rest of the
probes contain all possible single or double mismatches (1MM or 2MM) against the wild
type target, avoiding the free energy penalty coming from interaction between two mis-
matches and a mismatch located close to the edge of the helix structure [7]. From an
experimental point of view: for each probe eight identical spots are present on the microar-
ray and the median of the eight technical replicates is used as the hybridization signal I of
the probe. The hybridization signal will be the highest for spots with a perfect matching
sequencing, while the intensity will decrease depending on the number and kind of mis-
match mutations.
Sample preparation and microarray experiments
To obtain synthetic ssDNA mixtures, a PCR reaction was performed on the double-stranded
sequence-verified gBlocks Gene Fragments (IDT, Leuven, Belgium) which we will refer to as
gBlocks. The PCR reaction comprised of 0.4 μM forward (5’-GTCCTGCACCAGTAATATGC-3’),
0.4 μM reverse (5’-CTGGCGTCATAGCTGTTTCCTGTGTGAGTATTAACCTTATGTGTGACA-3’)
primers (Eurogentec, Seraing, Belgium), 2 mM MgSO4, 0.2 mM of each dNTP, 2 U Platinum
Taq DNA High-Fidelity Polymerase (Life Technologies, Ghent, Belgium), and 0.5 ng gBlocks
DNA in a final volume of 50 μl. The reverse primer has a phosphate modification at the 5’ end.
The DNA was amplified through 35 cyles (95˚C, 30 s; 55˚C, 30 s; 72˚C, 30s) with a Veriti ther-
mal cyler (Life Technologies). Amplicons were purified using Qiagen PCR purification kit
(Qiagen, Hilden, Germany), according to manufacturer’s protocol. A lambda exonuclease
treatment (Fermentas, St.Leon-Rot, Germany) was performed on the purified PCR product
according to manufacturer’s protocol. Lambda exonuclease selectively digests the 5’-phosphor-
ylated strand of double-stranded DNA. The obtained ssDNA was analysed on a FlashGel DNA
system (Lonza, Slough, UK), and concentration was measured on a NanoDrop
spectrophotometer.
For the clinical samples, the DNA was extracted using the Gentra Puregene Tissue Kit (Qia-
gen) according to manufacturer’s protocol. 100 ng DNA was used in the PCR reaction. Sam-
ples were also sequenced by Sanger sequencing for KRAS status in an ISO15189 accredited lab.
No ethical approval was asked specifically for this study since the samples were send in for
diagnostic purposes. The samples come from a biobank that are kept at the Center for Medical
Genetics, Ghent. No URL is available since this is not a public biobank. All samples were
obtained before the beginning of the study. No one of the authors were treating physicians nor
had they any interaction with the subjects.
The microarray experiments of the first experiment set used a total ssDNA concentration
of 5 nM, the second and third experimental set used 10 nM. The microarray experiments
were performed using the commercially available Agilent G2565BA scanner system. A Cya-
nine-3 (Cy-3) labeled Barcode sequence was added to the hybridization mixture (Cy3-5’-
AAAAACTGGCGTCATAGCTGTTTCCTGTGTGA-3’) to avoid direct labelling of the tar-
get sequences. The barcode was diluted in nuclease-free water to a final concentration of
0.05 μM together with ssDNA (the concentration depends on the experiment), 5 μl 10×
blocking agent and 25 μl 2× GEx hybridization buffer HI-RPM. The hybridization mixture
was centrifuged at 13000 rpm for 1 minute and each microarray of the 8×15K custom Agilent
slides was loaded with 40 μl of the mixture. The hybridization occurred in an Agilent oven at
65˚C for 17h with rotor setting 10 and the washing was performed according to the instruc-
tions of the manufacturer. Samples were analyzed using the Agilent Feature Extraction soft-
ware (GE1 v5 95 Feb07), combining dynamic auto-focus intensity measurements with
automatic background signal subtraction to improve the signal-to-noise ratio.
DNA mutation hybridization framework
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Results
Modelling of DNA thermodynamics
The clinical goal of this work is to differentiate samples containing only wild type (wt) DNA
from samples consisting of a mixture of wild type with a minority of one of the mutant (mut)
sequences, see Table 2. In the former case of a pure wild type sample, the microarray intensity
I for each probe (microarray spot) can be modeled by the theory of the Langmuir isotherm
[12–14]:
Iwt ¼ Acwte
  DG=RT ð1Þ
where A is a device dependent optical proportionality factor, R the ideal gas constant, T the
experimental temperature and most importantly ΔG the probe-target affinity. For a sample
with a mix of wild type and mutant DNA, competitive hybridization to each probe occurs and
leads to
Imix ¼ Iwt þ Imut
¼ Aðcwte  DGwt=RT þ cmute  DGmut=RTÞ
ð2Þ
where the free energies ΔGwt and ΔGmut are both with respect to the same probe under
consideration.
We apply this theory to extract sequence information from the intensity data since ΔG is
sequence dependent. Hereto we perform one reference measurement with a known wild type
sample and use this reference data in a scatter plot for each test sample. In these plots each
point corresponds to one probe from the probeset (Table 3). When the test sample is also
purely wild type, the resulting data points will lie on the diagonal identity line; when the sam-
ple is a wild type—mutant mix, the result will typically look like those presented in Fig 1. Since
the mutant is present in minority, the contribution of the second term in Eq (2) will nearly
always be negligible. This leads to a vast amount of data points on the identity diagonal (black
circles in Fig 1). However, some of the probes will have a nucleotide variation that matches the
mutant both in base position and type (Watson-Crick), which results in an increased affinity
towards the mutant DNA, i.e. −ΔGmut > −ΔGwt. These probes (red squares in Fig 1) will have
an increased intensity. Finally there are probes with a nucleotide variation that matches the
mutant in position but not in type (blue triangles in Fig 1). We name these three types of data
points respectively the reference branch, the mutant branch and the side branch. More details
on this branched structure can be found in Hadiwikarta et al. [15].
The information in this plot type leads to two practical consequences. Firstly, it provides
quantitative information on the detection limit of a mutant in minority, secondly it can be
used to perform hypothesis testing for presence of a mutant. The following two sections elabo-
rate on this.
Statistical testing for the presence of a mutant
To detect a mutation in a tumor sample, we need a statistical test to accept or reject each of the
hypotheses on the presence of a specific mutation. By design we know the sequences of all
microarray probes, each of the hypotheses can be associated with a subset of those probes
which contain a specific mutation type and position. (Note that in our case the subsets will
always contain more than one probe since the probeset of Table 3 includes probes with two
mutations.) If the data points of a subset all fall in the reference branch, the hypothesis is falsi-
fied, i.e. this mutation is not present in the sample. Else, if the data points have an increased
intensity over the reference branch and form the most deviating branch like the squares in
DNA mutation hybridization framework
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Fig 1, this specific mutation type and position is present in the sample. Otherwise, if the data
points are increased in intensity but are not the most deviating ones, like the triangles in Fig 1,
the mutations position is confirmed but its base type hypothesis is falsified. For a practical
implementation we perform locally weighted scatterplot smoothing (LOWESS) of the refer-
ence branch and calculate the vertical distance of all subset points to the reference line followed
by a Wilcoxon rank-sum test. (In Fig 1 the LOWESS of the reference branch is indicated as a
solid line called the reference line.) The Wilcoxon rank-sum is a conservative test, making very
Fig 1. Representative scatter plot: The intensity values from a mixture sample containing a mutant in minority (Imix,
y-axis) are plotted versus the intensity of a reference sample containing only wild type DNA (Iwt, x-axis). A curve is
drawn through the reference branch (black circles) using LOWESS smoothing and is called the reference line. The most
deviating branch (mutation branch, red squares) contains information about the mismatching nucleotide of the mutant. Probes
that do not match the nucleotide of the mutant but have nucleotide variations at the same position can be found in between
(side branches). The distance ρ is the difference between the mutation and reference branch and is a visual representation of
the change in free energy when a nucleotide mismatch mutation is introduced.
https://doi.org/10.1371/journal.pone.0177384.g001
DNA mutation hybridization framework
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few assumptions about the data. There is room for statistical fine tuning, but the resulting p-
values suffice for the present needs. In practice the p-values can be extremely small, therefore
we present them in a logarithmic format throughout the manuscript and define p0  −ln(p),
thus a high p0-value indicates a highly significant result.
Analysis framework for detection limit
In order to screen for the presence of a mutant, the mutation branch needs to be detectable
above the reference branch. Therefore a firm understanding of this relation is key to derive the
detection limit of a mutant in minority. Hereto, we denote the logarithm of this distance as ρ,
hence
r ¼ ln
Imix
Iwt
 
ð3Þ
From Eqs (1) and (2) one can derive the theoretical expression
r ¼ ln 1þ
cmut
cwt
e  DDG=RT
 
ð4Þ
where ΔΔG = ΔGmut − ΔGwt. To first order, according to the nearest neighbor model for free
energy of DNA, ΔΔG is equal for all probes of the mutation branch and corresponds to the spe-
cific affinity penalty of the mismatching nucleotide of the mutant [7]. Moreover, in Eq (4) the
device dependent factor A canceled out making ρ a purely physico-chemical parameter.
Finally, one can rewrite the equation as
er   1 ¼
cmut
cwt
e  DDG=RT ð5Þ
In this expression we find a linear relation with the relative mutant abundance cmut/cwt,
with intercept zero and a simple proportionality factor which is the physico-chemical impact
of the nucleotide mutation e−ΔΔG/RT. We will next show the validity of this relation experimen-
tally and use it to derive a limit of detection for the KRAS mutations of Table 2. Note that
although the theory predicts that the distance ρ is equal for all probes of the mutation branch,
the experimental results will show some deviations between the data points. This is due to
experimental conditions (not fully equilibrated system) and due to interaction effects of nucle-
otide mismatches [7]. In practice we are interested in ρ as a distance measure for the mutation
branch as a whole, therefore in the rest of this paper we use the median value of all data points
of the mutant branch and call this the distance ρ of the branch.
Assessing the limit of detection for relative concentrations of mutant
DNA
We next present experimental evidence that the vertical distance ρ between the mutation
branch and the reference line is quantitatively related to the relative abundance of the
mutant, indicated in %. In our hybridization model, this distance determines the detectabil-
ity of a mutation, and the corresponding relative concentration cmut/cwt is mutation depen-
dent. In order to get an estimate of the detection limit for each mutation, we start by
analyzing experiment set 1: the dilutions series of mutation 10C!G (or G12A in amino acid
notation) presented in Table 1. The results of these six experiments are presented in Fig 2,
which clearly show a deviating mutation branch in each subplot. We expect that the muta-
tion branch distance relates to the relative concentration cmut/cwt following Eq 5. The dilu-
tions series experiment shows the validity of this relation as can be seen in Fig 3. The
DNA mutation hybridization framework
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Fig 2. Scatter plot intensities of the 10C!G KRAS mutant using multiple relative concentrations: The intensity values from the mixed samples
(wild type with 10C!G mutant; G12A in amino acid notation) are shown on the y-axis, while the intensity values of the wild type reference are
shown on the x-axis. Data points below background intensity are removed. The plots show a decreasing relative mutant concentration, dilution factor 2.5.
The relative concentration, cmut/ctotal, is indicated as a percentage on top of each graph.
https://doi.org/10.1371/journal.pone.0177384.g002
DNA mutation hybridization framework
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Figure confirms that the profile passes through the origin and is linear to a degree sufficient
for our further analysis. Hence the profile is determined when a single measurement point is
available.
Next we apply the statistical test, described previously, on experiment set 1. For each sam-
ple, 12 mutations are possible: 3 on nucleotide position 9, 10, 12 and 13 (see Table 2). For
each possible mutation the hypothesis is tested whether its corresponding mutation branch
is deviating significantly from the reference branch, resulting in a p-value. The results are
shown visually in Fig 4 and also a summary is provided in S1 Table for reference. For each
sample a high statistical significance for a mutant hypothesis on position 10 is found. The
associated point mutation leads to the correct identification of mutant 10C!G for each sam-
ple. Note that, at position 10, the mutation branch distance ρ is decreasing with decreasing
mutant content as expected, but the statistical significance is untouched and remains invari-
ant over the whole concentration range. Therefore, the statistical results do not deviate from
Fig 3. A concentration profile of 10C!G (G12A amino acid mutation) based on Eq 5. The dashed line is a linear
fit with offset zero and a slope which corresponds to exp(−ΔΔG/RT).
https://doi.org/10.1371/journal.pone.0177384.g003
DNA mutation hybridization framework
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the physical observations that we performed previously and this provides strong confidence
in the method.
The concentration range results lead to two important conclusions. Firstly, the mutation
10C!G is still detectable at a relative concentration cmut/ctotal = 0.1% (as confirmed by the statis-
tical test). Secondly, the data in the 0.1% plot give a value of ρ 0.5, which we can subsequently
use as the threshold ρt for detection. Hence, we can infer detection limits for other mutations by
a measurement of ρ at a single concentration, which we do in the following section.
Assessing the limit of detection for multiple mutations
To check for more than one mutation in a hybridization experiment, we tested the 12 most
commonly reported KRAS mutations at a relative concentration of 5% (see Table 2) and used
a wild type sample as negative control. The result is shown in Fig 5, which clearly shows that
the concentration profile that corresponds to the weakest ΔΔG (which is the smallest slope)
still intersects with the threshold at the point cmut/cwt 0.008< 1%. This important result
means that the detection limit of the weakest mutation is well below 1%.
We next confirm this result using statistical analysis, using the same approach we applied
on experimental set 1 previously (Fig 4). As illustrated in Fig 6, each sample shows exactly one
high statistical significance and for each sample the correct mutant is retrieved. The statistical
results of the most significant nucleotide positions are also summarized in S2 Table.
Fig 4. Pie diagrams of the statistical results of experiment set 1: Concentration range experiment with gBlocks samples. Each diagram
corresponds to a relative concentration of the 10C!G mutant (G12A in amino acid notation) in the samples. The size of each pie is proportional to the
vertical distance between the mutation branch and reference branch (ρ). The colour of each pie diagram represents the statistical significance: p-values
below 0.01 are shown in blue while p-values above 0.01 are shown in orange. All values can be found in S1 Table for reference.
https://doi.org/10.1371/journal.pone.0177384.g004
DNA mutation hybridization framework
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Application to clinical samples
We analyzed seven blind coded clinical FFPE tumor samples for which sanger sequencing data
of the KRAS status was available. The samples were treated as described in Materials and
Methods and statistically analyzed leading to the results in S3 Table and Fig 7. For each of the
seven samples the p0-values indicated one clear mutation. After decoding of the samples, the
results of the last column of the table appeared in full agreement with sequencing data.
Summary of statistical tests
As a summary of the statistical tests we first note that in each sample the correct mutant was
retrieved as the most statistically significant hypothesis. As a further analysis we combine all
experimental results and present them in Fig 8. Here, for each sample, the p0-value of the most
Fig 5. Plot of concentration profile similar to Fig 3 for all 12 KRAS mutations, based on experiment set 2.
The profile is known to be linear, hence a single experiment per mutation type suffices. A higher slope corresponds
to a stronger mutation. The bold dotted line is 10C!G (G12A in amino acid notation), the same mutation we used in
Fig 3. The horizontal dashed line corresponds to the threshold value ρt 0.5 from which we can derive the
concentration threshold for each mutation.
https://doi.org/10.1371/journal.pone.0177384.g005
DNA mutation hybridization framework
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Fig 6. Pie diagrams of the statistical results of experiment set 2: 12 KRAS samples with each mutant present
at 5% concentration. The size of each pie is proportional to the vertical distance between the mutation branch and
reference branch (ρ). The colour of each pie diagram represents the statistical significance: p-values below 0.01 are
shown in blue while p-values above 0.01 are shown in orange. All values can be found in S2 Table for reference.
https://doi.org/10.1371/journal.pone.0177384.g006
DNA mutation hybridization framework
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significant hypothesis (the true mutation) is indicated and compared with the p0-values of the
other hypotheses (the other three nucleotides). This figure shows a clear gap between the cor-
rect and false hypotheses indicating that it is not difficult to set a significance threshold to dis-
tinguish true from false positives. As an extra test, the p0-values of the WT experiments (nr. 19
and 27) are also well below those of the mutant hypotheses in mutant-containing samples.
Discussion
In this paper we developed a framework to assess the capability of hybridization to detect
point mutations present in a small percentage in mixed samples. We use a solid support
Fig 7. Pie diagrams of the statistical results of experiment set 3: Blinded clinical samples. The size of each pie is proportional to the vertical distance
between the mutation branch and reference branch (ρ). The colour of each pie diagram represents the statistical significance: p-values below 0.01 are shown
in blue while p-values above 0.01 are shown in orange. All values can be found in S3 Table for reference.
https://doi.org/10.1371/journal.pone.0177384.g007
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nucleic acid platform and consider 12 clinically highly relevant hotspot point mutations in
exon 2 of the KRAS oncogene. Clinical samples for which this test could be used always contain
a mixture of cancer and non-cancer cells, the former is in minority and is a potential carrier of
a point mutation. Using a dilution series with a decreasing amount of mutant DNA we first
show a quantitative agreement between measured values and a suited thermodynamics theory.
Using this agreement we next determine the detection limit of mutant DNA without the need
to perform dilution series for each mutation. The results show that each mutation can be
detected at levels at least as low as 1% of mutant, which makes it clinically highly relevant.
The current manuscript builds on previous work on DNA hybridization [6–8, 12, 15, 16],
the novelty of the presented work is in the use of DNA thermodynamics in the design of an
assay capable to detect multiple and specific mutations with a well-defined limit of detection
derived from physical principles and capable to perform this on clinical FFPE samples. The
example of the FFPE samples illustrates that our method can deal with the limited quality and
heterogeneity of the tissue material. Due to the intrinsic parallel character of the microarray
technology, this approach makes it possible to screen for hundreds of different point muta-
tions in a single run.
This work shows that enzyme-free detection of point mutations via DNA hybridization is a
highly quantitative technique with an accuracy, robustness and parallelization suited for clini-
cal applications. The results also support and complement the research efforts in hybridiza-
tion-based methods [17–27]. By using the concepts of DNA thermodynamics upon
hybridization, the current technique has the advantage that mutations with low relative abun-
dance can be detected in a higher parallelization level than PCR-based methods. In compari-
son to sequencing techniques, we can state that the process of hybridization is a very
elementary reaction in which no enzymes are involved, which opens doors for further low-
tech detection assays at physiological conditions [28]. Last but not least, the framework
Fig 8. A summary of the statistical results of all three experiment sets. The p0-value of the most significant hypothesis (the true mutation) is indicated by
a square. The p0-values of all the hypotheses at the other three nucleotides are indicated with a dot. Raw data can be found in S1, S2 and S3 Tables.
https://doi.org/10.1371/journal.pone.0177384.g008
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presented in this paper is platform-free and shows the advantage of a good description of the
underlying physico-chemical principles.
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